Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Riccardo Pariano"'
Autor:
Eduard Vieta, Brendon Stubbs, Andrea de Bartolomeis, André F. Carvalho, Domenico De Berardis, Riccardo Pariano, Michele Fornaro, Marco Solmi, Stefano Novello, Michael Berk, Andrea Fusco, Nicola Veronese, Annalisa Anastasia
Publikováno v:
Fornaro, M, Anastasia, A, Novello, S, Fusco, A, Pariano, R, De Berardis, D, Solmi, M, Veronese, N, Stubbs, B, Vieta, E, Berk, M, de Bartolomeis, A & Carvalho, A F 2018, ' The Emergence of loss of efficacy during Antidepressant Drug Treatment for Major Depressive Disorder : An Integrative Review of Evidence, Mechanisms, and Clinical Implications ', Pharmacological Research . https://doi.org/10.1016/j.phrs.2018.10.025
The re-emergence (i.e. ‘breakthrough’) of depressive symptoms despite maintenance treatment of depression with antidepressant drugs is a complex clinical phenomenon referred to as tolerance. Herein we critically appraise evidence from both pre-cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40e13b7649b1ecbcc092db1e83051855
https://doi.org/10.1016/j.phrs.2018.10.025
https://doi.org/10.1016/j.phrs.2018.10.025
Autor:
Rita Genesio, Mario Capasso, Immacolata Andolfo, Marta Matrone, Riccardo Pariano, Annarita Barone, Antonella Gambale, Giuseppina Vitiello, Lucio Nitsch, Felice Iasevoli, Elisabetta F. Buonaguro, A. de Bartolomeis, Mariateresa Falco, Licia Vellucci, Federica Milandri, Achille Iolascon, Piero Pignataro
Publikováno v:
European Neuropsychopharmacology. 40:S107-S108
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6079d11b2aab7f0a094095d4d459597
https://doi.org/10.1016/j.euroneuro.2020.09.142
https://doi.org/10.1016/j.euroneuro.2020.09.142
Autor:
Marta Matrone, Danilo Notar Francesco, Federica Milandri, Luigi D’Ambrosio, Camilla Avagliano, Riccardo Pariano, Eugenio Razzino, Mariateresa Ciccarelli, Andrea de Bartolomeis, Benedetta Altavilla, Annarita Barone, Felice Iasevoli, Licia Vellucci
Publikováno v:
Schizophrenia Bulletin
Background Clozapine is the gold standard for Treatment Resistant Schizophrenia (TRS) and its use is strongly recommended after failure of two/three antipsychotics. Nonetheless, prescribing trends do not appear to follow the global guidelines and swi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b98de8836984ded0070907dd71a5a1
https://doi.org/10.1093/schbul/sbaa031.268
https://doi.org/10.1093/schbul/sbaa031.268
Autor:
Camilla Avagliano, Licia Vellucci, Felice Iasevoli, Riccardo Pariano, Eugenio Razzino, Luigi D’Ambrosio, Mariateresa Ciccarelli, Benedetta Altavilla, Federica Milandri, Danilo Notar Francesco, Annarita Barone, Marta Matrone, Andrea de Bartolomeis
Publikováno v:
Schizophrenia Bulletin
Background Earlier age at schizophrenia onset has been associated with worse prognosis, greater symptom severity, social withdrawal, poorer cognitive performances, however much heterogeneity and inconsistency in findings have been reported in these s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91126b922a50e2af0c11d6db99569d1c
https://doi.org/10.1093/schbul/sbaa028.051
https://doi.org/10.1093/schbul/sbaa028.051